CGON — CG Oncology Inc. stock price, charts and financials

QT78CG Oncology Inc.

CG Oncology Inc. (NASDAQ: CGON) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
74.95
-0.15-0.20%
OverviewShort InterestFilings
CGONQT78CG Oncology Inc.·NASDAQ
74.95-0.20%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
BLTE+1.70%$165.82CAI+1.17%$23.00ERAS-2.39%$17.97SRRK-3.33%$51.16CNTA+0.00%$40.50MIRM-2.62%$98.01XENE-0.23%$63.22PTCT+0.31%$73.54
Snapshot
Index-P/E-EPS (ttm)-Insider Own14.30%Shs Outstand88.20MPerf Week5.49%
Market Cap6.62BForward P/E-EPS next Y-2.82Insider Trans2.51%Shs Float65.82MPerf Month2.43%
Enterprise Value6.61BPEG0.73EPS next Q-Inst Own-Short Float18.39%Perf Quarter8.56%
Income-224.55MP/S-EPS this Y-Inst Trans-Short Ratio11.44Perf Half Y52.64%
Sales6.23MP/B6.44EPS next Y-2.37%ROA-20.67%Short Interest12.11MPerf YTD80.88%
Book/sh-P/C-EPS next 5Y-ROE-25.20%52W High76.85 -2.47%Perf Year196.96%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-24.30%52W Low23.60 217.55%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin-82.69%Volatility4.50% 5.28%Perf 5Y-
Dividend TTM-EV/Sales-EPS Y/Y TTM-65.25%Oper. Margin-4056.18%ATR (14)3.75Perf 10Y-
Dividend Ex-Date-Quick Ratio22.20Sales Y/Y TTM-Profit Margin-3602.68%RSI (14)58.37Recom2.00
Dividend Gr. 3/5Y-Current Ratio22.22EPS Q/Q-57.78%SMA204.84%Beta1.21Target Price87.20
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5012.17%Rel Volume0.58Prev Close75.10
Employees142LT Debt/Eq0.01EarningsNov 12SMA20030.51%Avg Volume1.06MPrice74.95
IPO DateJan 25, 2024Option/ShortYes / YesEPS/Sales Surpr.-27.76% 139.05%Net Debt/EBITDA0.05Volume610,476Change-0.20%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedTruist FinancialBuy$82 → $85
Jul-29-26ReiteratedH.C. WainwrightBuy$75 → $100
May-14-26ReiteratedTruist SecuritiesBuy$75 → $82
May-11-26ReiteratedRBC CapitalOutperform$79 → $81
May-11-26ReiteratedTruist SecuritiesBuy$75 → $82
May-11-26ReiteratedWedbushOutperform$70 → $80
Apr-27-26ReiteratedRBC CapitalOutperform$73 → $79
Mar-26-26ReiteratedUBS$60 → $90
Feb-10-26ReiteratedTruist SecuritiesBuy$66 → $75
Jan-21-26ReiteratedRBC CapitalOutperform$61 → $73
Latest News
Aug-07-26
Aug-07-2602:38PM
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79Benzinga
Aug-06-26
Aug-06-2610:51AM
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimateszacks.com
08:15AM
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.com
Jul-29-26
Jul-29-2607:39PM
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firmglobenewswire.com
Jul-27-26
Jul-27-2606:45PM
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncologyglobenewswire.com
Jul-19-26
Jul-19-2608:26PM
CG Oncology: Priced To Perfection On Future Pipeline SuccessSeekingAlpha
Jul-16-26
Jul-16-2604:38PM
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 DealBenzinga
Jul-13-26
Jul-13-2610:07AM
CG Oncology Stock Gains 12% in Three Months: What's Driving It?zacks.com
Jul-07-26
Jul-07-2610:28AM
SBIO: Biotech Breakthrough Opportunities Screened For Cash BurnSeekingAlpha
Company

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue641———
Cost of Goods Sold Incl. D&A12582———
Gross Profit-6-1-81———
Selling, General and Administrative Excl. Other917434———
Research and Development15711782———
Other Operating Expense0-1-82———
Operating Income-252-191-115———
Interest Expense
000———
Unusual Expense
——————
Non-Operating Income (Expense)273027———
Net Income Before Taxes-224-161-88———
Income Taxes
000———
Consolidated Net Income-224-161-88———
Net Income From Continuing Operations-224-161-88———
Net Income-224-161-88———
EPS (Recurring)-2.70-2.08-1.41———
EPS (Basic, Before Extraordinaries)-2.70-2.08-1.41———
EPS (Diluted)-2.70-2.08-1.41———
EBITDA-221-160-88———
Other After Tax Adjustments
——————
Stock Option Compensation Expense
——————
Price To Earnings Ratio
——————
Price To Sales Ratio1,099.28799.261,778.16———
Gross Margin-100.00-25.00-8,100.00———
Operating Margin-4,200.00-4,775.00-11,500.00———
Net Margin-3,733.33-4,025.00-8,800.00———
Shares Outstanding887762———
Market Capitalization6,5963,1971,778———
Operating Lease Expense
——————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$82.93$66.26$49.59$32.93$16.26● Close Price0.00M12.50M25.00M37.50M50.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
POST LEONARD EDirectorJul 15 '26Option Exercise0.601,0006001,000Jul 17
POST LEONARD EDirectorJul 15 '26Sale71.171,00071,1700Jul 17
Mulay JamesDirectorJul 10 '26Option Exercise26.6324,165643,51424,165Jul 14
Mulay JamesDirectorJul 10 '26Sale75.1624,1651,816,2410Jul 14
Liu Brian Guan-ChyunDirectorJun 25 '26Buy66.87371,08524,814,4541,886,236Jun 29
POST LEONARD EDirectorJun 24 '26Sale70.005,000350,0000Jun 25
POST LEONARD EDirectorJun 24 '26Option Exercise0.605,0003,0005,000Jun 25
POST LEONARD EDirectorJun 22 '26Option Exercise0.605,0003,0005,000Jun 23
POST LEONARD EDirectorJun 22 '26Sale65.005,000325,0000Jun 23
Mulay JamesDirectorJun 15 '26Option Exercise9.641,96418,9261,310Jun 16
Mulay JamesDirectorJun 15 '26Sale60.121,31078,7570Jun 16
POST LEONARD EDirectorJun 04 '26Option Exercise0.601,0006001,000Jun 05
POST LEONARD EDirectorJun 04 '26Sale54.501,00054,5000Jun 05
Mulay JamesDirectorApr 17 '26Option Exercise36.6315,600571,42815,600Apr 20
Mulay JamesDirectorApr 17 '26Sale73.0115,6001,138,9560Apr 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.